Tests serum thymosin β4 as a biomarker distinguishing nonalcoholic steatohepatitis (NASH) from simple nonalcoholic fatty liver (NAFL)—a critical and clinically challenging differentiation since NASH carries fibrosis risk but currently requires liver biopsy. In 24 NAFL and 21 NASH patients, serum TB4 differed significantly between groups and correlated with the NAFLD activity score (NAS), performing comparably to oxidative stress marker 8-OHdG. Provides the first evidence for serum TB4 as a non-invasive NASH discriminator—enabling potential biopsy-sparing risk stratification.
Jiang, Yong; Han, Tao; Zhang, Zhi-Guang; Zhang, Ying; Qi, Feng-Xiang